Unternehmen Novartis AG London S.E.

Unternehmen Novartis AG London S.E.

A0NGS8

CH0038459415

0QM7

Pharmazeutika

Analystenschätzungen

Aktien

A0NGS8

CH0038459415

0QM7

Pharmazeutika

Analystenschätzungen

Kurzporträt

Umsatz nach Geschäftsbereich

Umsatz je Region

Manager

Aufsichtsräte

Anteilsklasse

Aktionäre

Unternehmensbesitz

Unternehmenskontakt

Konzerngesellschaften

Sektor

Umsatz nach Geschäftsbereich

Umsatz je Region

Ratings für Novartis AG

Verlauf des Gewinns je Aktie

Quartalsgewinne - Abweichungsrate

Sektor Pharmazeutika - Andere

Kurzporträt

Umsatz nach Geschäftsbereich

Umsatz je Region

Manager

Aufsichtsräte

Anteilsklasse

Aktionäre

Unternehmensbesitz

Unternehmenskontakt

Konzerngesellschaften

Sektor

Umsatz nach Geschäftsbereich

Umsatz je Region

Ratings für Novartis AG

Verlauf des Gewinns je Aktie

Quartalsgewinne - Abweichungsrate

Sektor Pharmazeutika - Andere

Markt geschlossen - London S.E. Andere Börsenplätze 17:59:30 21.05.2018			% 5 Tage	% 1. Jan.
76.86 ^CHF	-1.00%		-0.77%	-.--%

31.05.	UBS belässt Novartis auf 'Buy' - Ziel 108 Franken	DP
31.05.	Europäische Aktien schließen im Freitagshandel höher; Flash-Inflation der Eurozone steigt stärker als erwartet	MT

Novartis AG zählt zu den weltweit führenden Unternehmen für Konzipierung, Herstellung und Vertrieb von Pharmaprodukten. Der Umsatz (ausgenommen aufgegebenen Geschäftsbereiche) ist wie folgt auf die verschiedenen therapeutische bereiche verteilt:

- Onkologie (29,9%);

- Immunologie (17,2%);

- Herz-Kreislauf-, Nieren- und Stoffwechselerkrankungen (14,1%);

- Neurologie (8,9%).

Der restliche Umsatz (29,9%) wird aus der Auftragsfertigung von Pharmaprodukte erzielt.

Ende 2023 verfügte die Novartis AG über 33 Produktionsstandorte auf der ganzen Welt.

Die geographische Umsatzverteilung sieht aus wie folgt: Europa (33%), USA (39,5%), Asien / Afrika / Australasien (20,5%), Kanada und Lateinamerika (7%).

CHF in Millionen	2022	Gewichtung	2023	Gewichtung	Delta
Established Brands 30,0 %	-	-	12 238	30,0 %	-
Oncology 29,9 %	-	-	12 213	29,9 %	-
Immunology 17,2 %	-	-	7 008	17,2 %	-
Cardiovascular, Renal and Metabolic 14,1 %	-	-	5 743	14,1 %	-
Neuroscience 8,9 %	-	-	3 633	8,9 %	-

CHF in Millionen	2022	Gewichtung	2023	Gewichtung	Delta
United States 39,5 %	16 860	34,9 %	16 139	39,5 %	-4.28%
Europe 18,9 %	10 469	21,7 %	7 704	18,9 %	-26.41%
Asia/Africa/Australasia 9,1 %	4 975	10,3 %	3 700	9,1 %	-25.63%
Germany 7,4 %	4 086	8,5 %	3 026	7,4 %	-25.94%
China 7,2 %	2 987	6,2 %	2 936	7,2 %	-1.73%
Canada and Latin America 7,0 %	3 709	7,7 %	2 854	7,0 %	-23.04%
Japan 4,2 %	2 106	4,4 %	1 729	4,2 %	-17.90%
France 3,8 %	2 156	4,5 %	1 572	3,8 %	-27.09%
Switzerland 2,9 %	926	1,9 %	1 175	2,9 %	+26.88%

Manager	Titel	Alter	Seit
Vasant Narasimhan CEO	Chief Executive Officer	48	01.01.05
Harry Werner Kirsch DFI	Director of Finance/CFO	59	01.01.03
Shreeram Aradhye CTO	Chief Tech/Sci/R&D Officer	62	16.05.22
Steffen Lang COO	Chief Operating Officer	57	01.04.17
Klaus Moosmayer CMP	Compliance Officer	56	01.12.18
Samir Shah IRO	Public Communications Contact	63	01.01.04
Simon Brown PRN	Corporate Officer/Principal	-	01.08.13
Kees Roks AUD	Comptroller/Controller/Auditor	61	01.05.22
Linda Kanitra PRN	Corporate Officer/Principal	-	-
Robert Kowalski HRO	Human Resources Officer	56	01.09.21

Aufsichtsräte	Titel	Alter	Seit
Bill Winters BRD	Director/Board Member	62	01.01.13
Simon Moroney BRD	Director/Board Member	65	28.02.20
Hans Jörg Reinhardt CHM	Chairman	68	01.01.13
John Young BRD	Director/Board Member	60	07.03.23
Bridgette Heller BRD	Director/Board Member	62	28.02.20
Ton Büchner BRD	Director/Board Member	59	01.01.16
Charles Sawyers BRD	Director/Board Member	65	01.01.13
Nancy Andrews BRD	Director/Board Member	65	01.01.15
Patrice Bula BRD	Director/Board Member	68	28.02.19
Frans van Houten BRD	Director/Board Member	64	28.02.17

	Vote	Menge	Streubesitz	Konzerneigene Aktien	Total Float
Aktie A	1	2 189 930 497	1 866 336 959 ( 85,22 %)	233 443 766 ( 10,66 %)	85,22 %

Name	Aktien	%	Bewertung
NOVARTIS AG 6,625 %	145 083 991	6,625 %	14 087 Mio CHF
Sandoz Family Foundation 4,070 %	89 135 960	4,070 %	8 655 Mio CHF
UBS Asset Management Switzerland AG 3,123 %	68 391 910	3,123 %	6 640 Mio CHF
Universal-Investment-Gesellschaft mbH (Invt Mgmt) 0,3011 %	6 593 896	0,3011 %	640 Mio CHF
State Street Global Advisors Ltd. 0,2009 %	4 399 160	0,2009 %	427 Mio CHF
MFS International Singapore Pte Ltd. 0,1785 %	3 909 515	0,1785 %	380 Mio CHF
UBS AG (Investment Management) 0,1782 %	3 902 170	0,1782 %	379 Mio CHF
MFS International (UK) Ltd. 0,1778 %	3 893 811	0,1778 %	378 Mio CHF
La Mondiale SAM (Investment Portfolio) 0,1776 %	3 888 630	0,1776 %	378 Mio CHF
Sjunde AP-fonden 0,1652 %	3 618 724	0,1652 %	351 Mio CHF

Name	Aktien	%	Bewertung
PRIMECAP Management Co. 0,5670 %	12 417 755	0,5670 %	1 230 Mio CHF
Dodge & Cox 0,5641 %	12 353 985	0,5641 %	1 224 Mio CHF
Eaton Vance Management 0,3314 %	7 258 381	0,3314 %	719 Mio CHF
Dimensional Fund Advisors LP 0,2748 %	6 018 082	0,2748 %	596 Mio CHF
Loomis, Sayles & Co. LP 0,2702 %	5 917 972	0,2702 %	586 Mio CHF
Fiduciary Trust Company International 0,2603 %	5 700 550	0,2603 %	565 Mio CHF
U.S. Trust Company of Delaware 0,2273 %	4 977 839	0,2273 %	493 Mio CHF
Wellington Management Co. LLP 0,2096 %	4 589 350	0,2096 %	455 Mio CHF
Wells Fargo Bank NA 0,1826 %	3 997 877	0,1826 %	396 Mio CHF
The Ayco Co. LP 0,1397 %	3 059 361	0,1397 %	303 Mio CHF

Name	Aktien	%	Bewertung
LUKB Expert Fondsleitung AG -	64 694	-	6 Mio CHF
ATP Fondsmaeglerselskab A/S -	46 082	-	5 Mio CHF
Swiss Rock Asset Management AG -	19 614	-	2 Mio CHF
Niederer & Partners AG -	5 300	-	517 893 CHF
Liontrust Portfolio Management Ltd. -	474	-	46 317 CHF

Name	Aktien	%	Bewertung
NOVARTIS AG 6,63%	145 083 991	6,63%	14 086 822 744 $
MORPHOSYS AG 51,00%	19 235 375	51,00%	1 361 563 516 $
SANDOZ GROUP AG 2,99%	12 886 900	2,99%	437 689 512 $
NOVARTIS INDIA LIMITED 70,68%	17 450 680	70,68%	216 480 572 $
THIRD HARMONIC BIO, INC. 6,48%	2 642 762	6,48%	27 643 291 $
ERASCA, INC. 8,12%	12 307 692	8,12%	23 138 461 $
OCULIS HOLDING AG 4,68%	1 713 521	4,68%	20 476 576 $
MOLECULAR PARTNERS AG 4,78%	1 739 130	4,78%	6 238 607 $
PRECISION BIOSCIENCES, INC. 5,98%	413 581	5,98%	4 020 007 $

Novartis AG

Lichtstrasse 35

4056, Basel

+41 61 324 1111

http://www.novartis.com

Name	Kategorie und Branche
Novartis International AG Novartis International AG Pharmaceuticals: MajorHealth Technology Novartis International AG manages the Novartis Group. It provides administrative, financial, legal, and technical services. It also offers scientific consultation to the Group. The company was founded on December 13, 1989 and is headquartered in Basel, Switzerland.	Pharmaceuticals: Major
Novartis BioVenturesAG Novartis BioVenturesAG Investment ManagersFinance Part of Novartis AG, Novartis BioVenturesAG is an alternative investment manager. The company is based in Basel, Switzerland.	Investment Managers
NOVARTIS INDIA LIMITED	Pharmaceuticals: Major
Novartis Securities Investment Ltd. Novartis Securities Investment Ltd. Investment ManagersFinance Part of Novartis AG, Novartis Securities Investment Ltd. is an investment bank that offers investment advice. The company is located in Bermuda.	Investment Managers
EBEWE Pharma Ges.m.b.H. Nfg.KG EBEWE Pharma Ges.m.b.H. Nfg.KG Pharmaceuticals: MajorHealth Technology EBEWE Pharma Ges.m.b.H. Nfg.KG engages in the development and manufacture of injectable pharmaceutical specialties. The firm offers therapy solutions for colon, lung, breast, and prostate cancer. It also specializes in drug and pharmaceutical development, as well as preclinical studies. The company was founded in 1934 and is headquartered in Unterach am Attersee, Austria.	Pharmaceuticals: Major
Novartis Capital Corp. Novartis Capital Corp. Finance/Rental/LeasingFinance Novartis Capital Corp. engages in the manufacture of pharmaceutical products. The company is headquartered in East Hanover, NJ.	Finance/Rental/Leasing
Novartis Finance SA	Finance/Rental/Leasing
Sandoz GmbH Sandoz GmbH Pharmaceuticals: MajorHealth Technology Sandoz GmbH manufactures generic pharmaceuticals and biotechnological drugs. Its products includes bio-similars, inhalers, patches, injectables, and oral solids. The company was founded in 1946 and is headquartered in Kundl, Austria.	Pharmaceuticals: Major
Novartis Pharma AG Novartis Pharma AG Pharmaceuticals: MajorHealth Technology Novartis Pharma AG engages in the research in as well as the production and distribution of pharmaceutical, chemical, medical, and biotechnological products. It also provides related services. The company was founded on October 25, 1989 and is headquartered in Basel, Switzerland.	Pharmaceuticals: Major
Novartis Holding AG Novartis Holding AG Financial ConglomeratesFinance Part of Novartis AG, Novartis Holding AG is a Swiss healthcare company that provides solutions to address the evolving needs of patients worldwide. The company is based in Basel, Switzerland. Novartis Holding specializes in Managed Access Programs and is committed to the discovery, development, and marketing of innovative products to improve the well-being of all Canadians. The company prides itself on its commitment to diversity and to nurturing an inclusive and inspiring environment.	Financial Conglomerates
Novartis UK Pension Scheme	Investment Managers
Novartis Investments SARL Novartis Investments SARL Financial ConglomeratesFinance Novartis Investments SARL is an investment holding company with interest in medicines and pharmaceuticals sector. The company was founded on July 05, 2002 and is headquartered in Luxembourg.	Financial Conglomerates
Novartis Investment Ltd.
Novartis Healthcare Pvt Ltd. Novartis Healthcare Pvt Ltd. Pharmaceuticals: MajorHealth Technology Part of Novartis AG, Novartis Healthcare Pvt Ltd. is an Indian company that manufactures and markets health care and nutritional products. The company is based in Mumbai, India. The company was founded in 1997. The CEO is Sanjay Prabhakar Murdeshwar.	Pharmaceuticals: Major
Alcon Ophthalmika GmbH
Novartis Investment Ltd. (2120)
Novartis Services, Inc.
Sandoz Pvt Ltd. Sandoz Pvt Ltd. Pharmaceuticals: GenericHealth Technology Part of Novartis AG, Sandoz Pvt Ltd. is an Indian company that develops, manufactures and markets generic pharmaceutical products. The company is based in Mumbai, India and was founded in 1995.	Pharmaceuticals: Generic
Novartis Pharma GmbH Novartis Pharma GmbH Pharmaceuticals: MajorHealth Technology Novartis Pharma GmbH engages in the production and sale of pharmaceutical products. The firm establishes and operates institutes for the development of medicinal products. It also conducts research and development in the field of pharmacy. The company was founded by Johann Rudolf Geigy-Gemuseus in 1758 and is headquartered in Vienna, Austria.	Pharmaceuticals: Major

Trading Rating

Investment Rating

ESG Refinitiv

Mehr Ratings

Verkaufen

Kaufen

Durchschnittl. Empfehlung

AUFSTOCKEN

Anzahl Analysten

Letzter Schlusskurs

103.1 USD

Mittleres Kursziel

108.8 USD

Abstand / Durchschnittliches Kursziel

+5.53%

Analystenschätzungen

Entwicklung der Schätzungen

Unternehmenstermine

	% 1. Jan.	Kap.
ELI LILLY AND COMPANY	+40.73%	739 Mrd.
NOVO NORDISK A/S	+32.83%	598 Mrd.
JOHNSON & JOHNSON	-6.30%	353 Mrd.
MERCK & CO., INC.	+15.15%	318 Mrd.
ABBVIE INC.	+4.05%	285 Mrd.
ASTRAZENECA PLC	+15.00%	240 Mrd.
ROCHE HOLDING AG	-5.52%	206 Mrd.
AMGEN INC.	+6.17%	164 Mrd.
PFIZER, INC.	-0.45%	162 Mrd.

Pharmazeutika - Andere

Gesundheitspflege

Pharmazie und Biotechnologie

Pharmazie und Biotechnologie

Pharmazeutika

Pharmazeutika - Andere